Background And Aims: Chimeric antigen receptor (CAR)-T cell therapy is a novel type of immunotherapy. However, the use of CAR-T cells to treat acute myeloid leukaemia (AML) has limitations. B7-H3 is expressed in several malignancies, including some types of AML cells. However, its expression in normal tissues is low. Therefore, B7-H3 is ideal for targeted AML therapy.
Materials And Methods: First, we constructed B7-H3 CAR that can target B7-H3, and then constructed B7-H3-CAR-T cells in vitro, which were co-incubated with six AML cell lines expressing different levels of B7-H3, respectively. The toxicity and cytokines were detected by flow cytometry. In vivo, AML model was established in B-NSG mice to study the toxicity of B7-H3-CAR T on AML cells.
Results: In vitro functional tests showed that B7-H3-CAR-T cells were cytotoxic to B7-H3-positive AML tumor cells and had good scavenging effect on B7-H3-expressing AML cell lines, and the cytokine results were consistent. In vivo, B7-H3-CAR-T cells significantly inhibited tumor cell growth in a mouse model of AML, prolonging mouse survival compared with controls.
Conclusion: B7-H3-CAR-T cells may serve as a novel therapeutic method for the targeted treatment of AML.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026503 | PMC |
| http://dx.doi.org/10.1186/s40001-023-01049-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of B7-H3 targeted CAR-T cells for renal cell carcinoma therapy: in vitro and in vivo efficacy.
Clin Transl Oncol
November 2024
Institute of Clinical Medicine, the Second Affiliated Hospital of Hainan Medical University, 368 Yehai Avenue, Haikou, 570311, Hainan, China.
Article Synopsis
- * Researchers confirmed high B7-H3 expression in RCC using various methods, developed a B7-H3-specific CAR-T cell, and proved their effectiveness in lab experiments and mouse models, highlighting increased cytotoxic activity and tumor growth inhibition.
- * The findings suggest that B7-H3 CAR-T cells could be a viable immunotherapy option for treating RCC, showing promise in targeting and destroying cancer cells.
Preclinical assessment of the efficacy of B7-H3 CAR-T in renal cell carcinoma.
Mol Immunol
December 2024
Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China; Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China. Electronic address:
Article Synopsis
- B7-H3 is a protein that is overexpressed in renal cell carcinoma (RCC) but not in normal tissues, making it a good target for cancer therapies.
- Researchers created advanced CAR-T cells that specifically target B7-H3, showing strong effectiveness against RCC tumors in lab tests and mouse models.
- The CAR-T cells demonstrated significant growth and impressive cytokine release when interacting with RCC cells, suggesting a promising new treatment approach for patients with RCC.
Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model.
Cancer Immunol Immunother
October 2024
World Premier International Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
Article Synopsis
- Glioblastoma multiforme (GBM) is a highly aggressive brain tumor that urgently needs new therapies; CAR T cell therapy has shown promise but is costly and time-intensive.
- Researchers are exploring CAR-transduced natural killer (NK) cells as an "off-the-shelf" immunotherapy alternative, which can avoid complications like graft-versus-host disease.
- Both CAR-T and CAR-NK cells targeting the B7-H3 protein demonstrated significant effectiveness in killing GBM cells in lab tests and in animal models, suggesting they could be viable treatment options for this aggressive cancer.
STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors.
J Clin Oncol
December 2024
Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA.
Article Synopsis
- B7-H3 is a promising target for immunotherapy in pediatric solid tumors due to its limited presence in critical organs, leading to a phase I trial testing B7-H3 CAR T cells in young patients with tough-to-treat tumors.
- Sixteen patients participated in the trial, with no serious dose-limiting toxicities from the first CAR T cell infusion, and one patient showed a partial response after a second infusion.
- The study concluded that while B7-H3 CAR T cells were generally tolerable and had limited anti-tumor effects, a strong CAR T cell response may be needed for better outcomes, emphasizing the importance of the patient's immune environment.
Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models.
Clin Cancer Res
October 2024
Department of Bone Marrow Transplantation and Cell Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.
Purpose: Clinical efficacy of chimeric antigen receptor (CAR) T cells against pediatric osteosarcoma (OS) has been limited. One strategy to improve efficacy may be to drive chemokine-mediated homing of CAR T cells to tumors. We sought to determine the primary chemokines secreted by OS and evaluate the efficacy of B7-H3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!